

118TH CONGRESS  
1ST SESSION

# S. 1373

To increase access to medication for opioid overdose reversal, and for other purposes.

---

IN THE SENATE OF THE UNITED STATES

APRIL 27, 2023

Mr. MARKEY (for himself, Mr. BOOKER, Mr. MARSHALL, and Mr. BRAUN) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

---

## A BILL

To increase access to medication for opioid overdose reversal, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Naloxone Affordability  
5 Act of 2023”.

6 **SEC. 2. GAO STUDY ON NALOXONE ACCESS.**

7 (a) IN GENERAL.—Not later than 1 year after the  
8 date of the enactment of this Act, the Comptroller General  
9 of the United States shall conduct a study on actions that

1 may be taken to protect access to naloxone for individuals  
2 seeking to purchase naloxone. Such study shall address—

3 (1) coverage of naloxone (in any available form)  
4 as an over-the-counter product—

5 (A) under a group health plan or group or  
6 individual health insurance coverage (as such  
7 terms are defined in section 2791 of the Public  
8 Health Service Act (42 U.S.C. 300gg–91)); and

9 (B) for individuals entitled to benefits  
10 under part A or enrolled under part B of title  
11 XVIII of the Social Security Act (42 U.S.C.  
12 1395 et seq.) or receiving medical assistance  
13 under a State plan under title XIX of such Act  
14 (42 U.S.C. 1396 et seq.) (or a waiver of such  
15 plan); and

16 (2) the out-of-pocket cost to consumers pur-  
17 chasing naloxone under any such plan or coverage.

18 (b) REPORT.—Not later than 1 year after the date  
19 of the enactment of this Act, the Comptroller General of  
20 the United States shall submit to Congress a report that  
21 contains the findings of the study conducted under sub-  
22 section (a).

○